Esophageal Cancer Clinical Trials

• Voluntarily sign the informed consent form and agree to follow the protocol requirements;

• No gender restriction;

• Age ≥18 years and ≤75 years at the time of signing the informed consent form;

• Expected survival time ≥3 months;

• Patients with unresectable, locally advanced recurrent or metastatic first-line esophageal squamous cell carcinoma;

• Must have at least one measurable target lesion as defined by RECIST v1.1;

• Must provide archived tumor tissue specimens from the primary or metastatic lesion within the past 3 years;

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;

• Toxicity from prior anti-tumor therapy must have recovered to ≤ Grade 1 as defined by NCI-CTCAE v6.0;

⁃ No severe cardiac dysfunction; left ventricular ejection fraction ≥50%;

⁃ Organ function levels must meet the specified requirements;

⁃ Coagulation function: International Normalized Ratio (INR) ≤1.5, and activated partial thromboplastin time (aPTT) ≤1.5 × upper limit of normal (ULN);

⁃ Urine protein ≤1+ or \<1000 mg/24h;

⁃ For premenopausal women of childbearing potential, a pregnancy test must be performed within 7 days before starting treatment; serum pregnancy test must be negative, and the patient must not be breastfeeding; all enrolled patients (regardless of male or female) must use adequate barrier contraception throughout the entire treatment period and for 7 months after the end of treatment.